NEW YORK (GenomeWeb) – Following Invitae's announcement earlier this week that its first quarter revenues rose sharply year over year, investment bank Leerink today upgraded shares of the company to an Outperform rating. 

Analyst Dan Leonard upgraded the San Francisco-based molecular diagnostics firm from a prior Market Perform rating but kept the price target on its shares at $20.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.